top of page

News

Portfolio: Portfolio

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Apr 11, 2023

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Apr 19, 2023

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Feb 18, 2023

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Sep 11, 2023

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

Dec 14, 2022

IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

SCG Singapore HSA IND Approval

July 11, 2022

SCG Cell Therapy Announces U.S FDA Clearance Of Investigational New Drug Application For SCG101, SCG’s Novel TCR-T Cell Therapy For Hepatitis B-Related Liver Cancers

SCG Singapore HSA IND Approval

May 9, 2022

SCG Cell Therapy Announces Clinical Trial Approval Of TCR-T Cell Therapy For Liver Cancer In Singapore

SCG China NMPA IND Approval

March 11, 2022

NMPA Clears IND For First T-Cell Receptor (TCR) T Cell Therapy To Treat Hepatitis B Virus (HBV) Associated Hepatocellular Carcinoma (HCC)

Lion FDA Fast Track Approval

December 23, 2021

Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma.

Lion USA FDA IND Approval

September 23, 2021

Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma.

bottom of page